Suivi cardiométabolique des malades traités par antipsychotiques, Mise au point. Mars, 2010. ,
Stress Axis Dysfunction: A Common Finding in Schizophrenia and the Metabolic Syndrome?, Pharmacopsychiatry, vol.26, pp.82-89, 2009. ,
DOI : 10.1159/000189776
A psychopathological study of a group of schizophrenic patients after attempting suicide. Are there two different clinical subtypes?, European Psychiatry, vol.18, issue.4, pp.190-192, 2003. ,
DOI : 10.1016/S0924-9338(03)00047-6
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation, Diabetic Medicine, vol.15, issue.7, pp.539-553, 1998. ,
DOI : 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
The metabolic syndrome???a new worldwide definition, The Lancet, vol.366, issue.9491, pp.1059-1062, 2005. ,
DOI : 10.1016/S0140-6736(05)67402-8
NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older, Diabetes, vol.52, issue.5, pp.1210-1214, 2003. ,
DOI : 10.2337/diabetes.52.5.1210
The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia, The Journal of Clinical Psychiatry, vol.60, issue.4, pp.215-220, 1999. ,
DOI : 10.4088/JCP.v60n0402
Antipsychotic-induced weight gain: a comprehensive research synthesis, American Journal of Psychiatry, vol.156, issue.11, pp.1686-1696, 1999. ,
Obesity Among Those with Mental Disorders, American Journal of Preventive Medicine, vol.36, issue.4, pp.341-350, 2009. ,
DOI : 10.1016/j.amepre.2008.11.020
The pathophysiology of cigarette smoking and cardiovascular disease, Journal of the American College of Cardiology, vol.43, issue.10, pp.1731-1738, 2004. ,
DOI : 10.1016/j.jacc.2003.12.047
Diagnosis and management of the metabolic syndrome Executive summary, National Heart, Lung, and Blood Institute Scientific Statement, pp.322-327, 2005. ,
Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR), Diabetic Medicine, vol.16, pp.442-443, 1999. ,
The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study, Diabetes & Metabolism, vol.29, issue.5, pp.526-532, 2003. ,
DOI : 10.1016/S1262-3636(07)70067-8
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial, Schizophrenia Research, vol.93, issue.1-3, pp.99-108, 2007. ,
DOI : 10.1016/j.schres.2007.03.029
HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events, New England Journal of Medicine, vol.357, issue.13, pp.1301-1310, 2007. ,
DOI : 10.1056/NEJMoa064278
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle, Journal of Clinical Psychiatry, vol.62, issue.S23, pp.45-66, 2001. ,
Safety of olanzapine, Journal of Clinical Psychiatry Monograph, vol.15, pp.19-21, 1997. ,
Management of Weight Gain Associated with Antipsychotics, Annals of Clinical Psychiatry, vol.15, issue.1, pp.49-53, 2003. ,
DOI : 10.3109/10401230309085669
Heart and Soul: Stress and the Metabolic Syndrome, Scandinavian Cardiovascular Journal, vol.7, issue.83, pp.172-177, 2001. ,
DOI : 10.1056/NEJM199902113400607
Mortality in DSM-IIIR schizophrenia, Schizophrenia Research, vol.7, issue.2, pp.109-116, 1992. ,
DOI : 10.1016/0920-9964(92)90040-C
Influences of Cardiorespiratory Fitness and Other Precursors on Cardiovascular Disease and All-Cause Mortality in Men and Women, 1996. ,
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study, Schizophrenia Research, vol.90, issue.1-3, pp.162-173, 2007. ,
DOI : 10.1016/j.schres.2006.09.025
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort, Schizophrenia Research, vol.119, issue.1-3, pp.101-109, 2010. ,
DOI : 10.1016/j.schres.2010.02.1030
RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist, Neuropharmacology, vol.36, issue.4-5, pp.4-5, 1997. ,
DOI : 10.1016/S0028-3908(97)00049-X
Le syndrome métabolique : Définition, épidémiologie, complications, Spectra Biologie, vol.145, pp.27-29, 2005. ,
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia, European Neuropsychopharmacology, vol.14, issue.1, pp.39-44, 2004. ,
DOI : 10.1016/S0924-977X(03)00061-0
Serum leptin levels increase rapidly after initiation of clozapine therapy, Molecular Psychiatry, vol.3, issue.1, pp.76-80, 1998. ,
DOI : 10.1038/sj.mp.4000352
The unhealthy lifestyle of people with schizophrenia, Psychological Medicine, vol.29, issue.3, pp.697-701, 1999. ,
DOI : 10.1017/S0033291798008186
Excess mortality of schizophrenia. A meta-analysis, The British Journal of Psychiatry, vol.171, issue.6, pp.502-508, 1997. ,
DOI : 10.1192/bjp.171.6.502
Causes of the excess mortality of schizophrenia, The British Journal of Psychiatry, vol.177, issue.3, pp.212-217, 2000. ,
DOI : 10.1192/bjp.177.3.212
A psychiatric rehabilitation approach to weight loss., Psychiatric Rehabilitation Journal, vol.29, issue.4, pp.267-273, 2006. ,
DOI : 10.2975/29.2006.267.273
Twenty-five year mortality of a community cohort with schizophrenia, The British Journal of Psychiatry, vol.196, issue.2, pp.116-121, 2010. ,
DOI : 10.1192/bjp.bp.109.067512
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications, Schizophrenia Research, vol.79, issue.2-3, pp.281-289, 2005. ,
DOI : 10.1016/j.schres.2005.04.010
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia, The British Journal of Psychiatry, vol.184, issue.47, pp.67-71, 2004. ,
DOI : 10.1192/bjp.184.47.s67
Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression, Journal of Psychiatric Research, vol.48, issue.1, pp.102-110, 2014. ,
DOI : 10.1016/j.jpsychires.2013.09.014
Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort, Schizophrenia Research, vol.98, pp.1950-2005, 2008. ,
Dyslipidemia and atypical antipsychotic drugs, Journal of Clinical Psychiatry, vol.65, pp.27-35, 2004. ,
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia, Journal of Clinical Psychiatry, vol.65, issue.S7, pp.4-18, 2004. ,
Metabolic issues and cardiovascular disease in patients with psychiatric disorders, The American Journal of Medicine Supplements, vol.118, pp.15-22, 2005. ,
DOI : 10.1016/j.amjmed.2005.01.046
Possible association of the pro-melanin-concentrating hormone gene witha greater body mass index as a side effect of the antipsychotic olanzapine, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol.83, issue.8, pp.1063-1069, 2007. ,
DOI : 10.1002/ajmg.b.30554
Metabolic Syndrome and Cardiovascular Disease, Journal of Psychopharmacology, vol.19, issue.6 suppl, pp.84-93, 2005. ,
DOI : 10.1177/0269881105058375
The metabolic syndrome: time for a critical appraisal, Response to Kahn et al. Diabetes Care 29, 2006. ,
Obesity and mental illness. Mod Trends Pharmacopsychiatry 26, pp.25-46, 2009. ,
Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat, Psychopharmacology, vol.152, issue.3, pp.256-267, 2000. ,
DOI : 10.1007/s002130000504
The association between schizophrenia and cancer: a population-based mortality study, Schizophrenia Research, vol.57, issue.2-3, pp.139-146, 2002. ,
DOI : 10.1016/S0920-9964(01)00308-5
Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study, JAMA, vol.285, pp.2109-2113, 2001. ,
Health Status of Individuals With Serious Mental Illness, Schizophrenia Bulletin, vol.32, issue.3, pp.584-589, 2006. ,
DOI : 10.1093/schbul/sbj048
Obesity among individuals with serious mental illness, Acta Psychiatrica Scandinavica, vol.173, issue.2, pp.306-313, 2006. ,
DOI : 10.1038/sj.ijo.0802204
The Association of Medical Comorbidity in Schizophrenia with Poor Physical and Mental Health, The Journal of Nervous & Mental Disease, vol.187, issue.8, pp.496-502, 1999. ,
DOI : 10.1097/00005053-199908000-00006
Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat, Psychopharmacology, vol.30, issue.1-2, pp.1-2, 1985. ,
DOI : 10.1007/BF00431709
Mental Disorders and Use of Cardiovascular Procedures After Myocardial Infarction, JAMA, vol.283, issue.4, pp.506-511, 2000. ,
DOI : 10.1001/jama.283.4.506
Affections m??taboliques et psychiatrie, EMC - Psychiatrie, vol.10, issue.2, 2013. ,
DOI : 10.1016/S0246-1072(13)60022-X
American college of Endocrinology position statement on the insulin resistance syndrome, Endocrine Practice, vol.9, pp.237-252, 2003. ,
Biochemical evidence of sympathetic hyperactivity in human hypertension., Hypertension, vol.17, issue.4_Suppl, pp.29-35, 1991. ,
DOI : 10.1161/01.HYP.17.4_Suppl.III29
Validation of a physical activity assessment tool for individuals with schizophrenia, Schizophrenia Research, vol.82, issue.2-3, pp.225-231, 2006. ,
DOI : 10.1016/j.schres.2005.10.020
Weight gain and antidepressants, Journal of Clinical Psychiatry, vol.61, issue.S11, pp.37-41, 2000. ,
Resting metabolic rate is reduced in patients treated with antidepressants, Biological Psychiatry, vol.20, issue.6, pp.692-695, 1985. ,
DOI : 10.1016/0006-3223(85)90107-6
The metabolic syndrome and mortality from cardiovascular disease and allcauses: findings from the National Health and Nutrition Examination Survey III Mortality Study, Atherosclerosis, vol.173, pp.309-314, 2004. ,
Increasing Prevalence of the Metabolic Syndrome Among U.S. Adults, Diabetes Care, vol.27, issue.10, pp.2444-2453, 2004. ,
DOI : 10.2337/diacare.27.10.2444
The Effects of Hypertension and Body Mass Index on Cognition in Schizophrenia, American Journal of Psychiatry, vol.167, issue.10, pp.1232-1239, 2010. ,
DOI : 10.1176/appi.ajp.2010.09091328
Weight Gain with Antidepressants and Lithium, Journal of Clinical Psychopharmacology, vol.8, issue.5, pp.323-353, 1988. ,
DOI : 10.1097/00004714-198810000-00003
Visceral fat and beta cell function in non-diabetic humans, Diabetologia, vol.113, issue.Suppl 1, pp.2090-2096, 2005. ,
DOI : 10.1007/s00125-005-1891-3
Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in Schizophrenia, American Journal of Psychiatry, vol.157, issue.11, pp.1835-1842, 2000. ,
DOI : 10.1176/appi.ajp.157.11.1835
Nicotine and tobacco use in schizophrenia, Medical illness and schizophrenia, pp.163-83, 2003. ,
Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity, Clinical Science, vol.110, issue.4, pp.409-425, 2006. ,
DOI : 10.1042/CS20050207
An exploratory analysis of criteria for the metabolic syndrome and its prediction of, 2005. ,
Schizophrenia, diabètes mellitus and antipsychotics, pp.382-391, 2004. ,
A unitary theory of stigmatisation: Pursuit of self-interest and routes to destigmatisation, The British Journal of Psychiatry, vol.178, issue.3, pp.207-215, 2001. ,
DOI : 10.1192/bjp.178.3.207
Prevalence of Diabetes and Impaired Glucose Tolerance in Patients Treated With Clozapine Compared With Patients Treated With Conventional Depot Neuroleptic Medications, The Journal of Clinical Psychiatry, vol.59, issue.6, pp.294-303, 1998. ,
DOI : 10.4088/JCP.v59n0604
High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia, International Clinical Psychopharmacology, vol.21, pp.93-98, 2006. ,
Components of the "Metabolic Syndrome" and Incidence of Type 2 Diabetes, Diabetes, vol.51, issue.10, pp.3120-3127, 2002. ,
DOI : 10.2337/diabetes.51.10.3120
Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide, American Journal of Psychiatry, vol.156, pp.1276-1278, 1999. ,
Excess mortality of mental disorder, The British Journal of Psychiatry, vol.173, issue.1, pp.11-53, 1998. ,
DOI : 10.1192/bjp.173.1.11
Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications, Primary Care Diabetes, vol.3, pp.5-15, 2009. ,
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics, Current Diabetes Reports, vol.58, issue.Suppl 1, pp.209-216, 2010. ,
DOI : 10.1007/s11892-010-0112-8
Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality, JAMA, vol.278, issue.4, pp.313-321, 1997. ,
DOI : 10.1001/jama.1997.03550040069040
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study, American Journal of Psychiatry, vol.157, issue.6, pp.975-981, 2000. ,
DOI : 10.1176/appi.ajp.157.6.975
Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality, The Journal of Clinical Psychiatry, vol.66, issue.09, pp.1116-1121, 2005. ,
DOI : 10.4088/JCP.v66n0905
Increasing Burden of Cardiovascular Disease : Current Knowledge and Future Directions for Research on Risk Factors, Circulation, vol.97, issue.11, pp.1095-1102, 1998. ,
DOI : 10.1161/01.CIR.97.11.1095
Clinical and research challenges in risk factors for cardiovascular diseases, European Heart Journal, vol.21, issue.23, pp.1917-1921, 2000. ,
DOI : 10.1053/euhj.1999.2221
Schizophrenia and increased risks of cardiovascular disease, American Heart Journal, vol.150, issue.6, pp.1115-1121, 2005. ,
DOI : 10.1016/j.ahj.2005.02.007
Effects of Antidepressants on Weight and on the Plasma Levels of Leptin, TNF-?? and Soluble TNF Receptors A Longitudinal Study in Patients Treated with Amitriptyline or Paroxetine, Neuropsychopharmacology, vol.23, issue.1, pp.13-19, 2000. ,
DOI : 10.1016/S0893-133X(00)00089-0
Changes in body mass index for individuals with and without schizophrenia, 1987???1996, Schizophrenia Research, vol.55, issue.3, pp.277-284, 1987. ,
DOI : 10.1016/S0920-9964(01)00256-0
Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects, Neuropsychopharmacology, vol.72, issue.2, pp.289-297, 2007. ,
DOI : 10.1038/sj.npp.1301209
Metformin and berberine prevent olanzapine-induces weight gain in rats, PloS One, vol.9, pp.377-382, 2014. ,
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome, Diabetes Care, vol.24, issue.4, pp.683-689, 2001. ,
DOI : 10.2337/diacare.24.4.683
Treatment of negative and cognitive symptoms, Current Psychiatry Reports, vol.18, issue.Suppl 2, pp.25-30, 1999. ,
DOI : 10.1007/s11920-999-0007-z
Triglyceride Concentration and Ischemic Heart Disease : An Eight-Year Follow-up in the Copenhagen Male Study, Circulation, vol.97, issue.11, pp.1029-1036, 1998. ,
DOI : 10.1161/01.CIR.97.11.1029
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin, Schizophrenia Research, vol.100, issue.1-3, pp.70-85, 2008. ,
DOI : 10.1016/j.schres.2007.11.026
Studies of depressive symptoms in schizophrenia, The British Journal of Psychiatry, vol.139, issue.2, pp.89-101, 1981. ,
DOI : 10.1192/bjp.139.2.89
The metabolic syndrome: time for a critical appraisal, Diabetologia, vol.28, issue.9, pp.1684-99, 2005. ,
DOI : 10.1007/s00125-005-1876-2
Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders, American Journal on Addictions, vol.14, issue.2, pp.106-123, 2005. ,
DOI : 10.1080/10550490590924728
Antipsychotic medication: effects on regulation of glucose and lipids, Expert Opinion on Pharmacotherapy, vol.156, issue.10, pp.1571-1582, 2001. ,
DOI : 10.1016/S0033-3182(99)71210-7
Bipolar Disorder, Obesity, and Pharmacotherapy-Associated Weight Gain, The Journal of Clinical Psychiatry, vol.64, issue.12, pp.1426-1435, 2003. ,
DOI : 10.4088/JCP.v64n1205
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic, Expert Opinion on Investigational Drugs, vol.12, issue.4, pp.655-662, 2003. ,
DOI : 10.1517/eoid.12.4.655.23750
Reduction in the incidence of type 2-diabetes with lifestyle intervention or metformin, New England Journal of Medicine, vol.346, pp.393-403, 2002. ,
Clozapine-associated diabetes, The American Journal of Medicine, vol.111, issue.9, pp.716-723, 2001. ,
DOI : 10.1016/S0002-9343(01)01000-2
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study, BMJ, vol.325, issue.7358, pp.325-243, 2002. ,
DOI : 10.1136/bmj.325.7358.243
Substance Abuse and Schizophrenia: Editors' Introduction, Schizophrenia Bulletin, vol.23, issue.2, pp.181-186, 1997. ,
DOI : 10.1093/schbul/23.2.181
URL : http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/23/2/181
High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia, Schizophrenia Research, vol.142, issue.1-3, pp.52-57, 2012. ,
DOI : 10.1016/j.schres.2012.09.003
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims, Pharmacoepidemiology and Drug Safety, vol.158, issue.6, pp.417-425, 2005. ,
DOI : 10.1002/pds.1092
Weight gain among schizophrenic patients treated with clozapine, American Journal of Psychiatry, vol.149, pp.689-690, 1992. ,
Smoking and Mental Illness, JAMA, vol.284, issue.20, pp.2606-2610, 2000. ,
DOI : 10.1001/jama.284.20.2606
Increased Mortality Among Patients Admitted With Major Psychiatric Disorders, The Journal of Clinical Psychiatry, vol.68, issue.06, pp.899-907, 2007. ,
DOI : 10.4088/JCP.v68n0612
Somatic Hospital Contacts, Invasive Cardiac Procedures, and Mortality From Heart Disease in Patients With Severe Mental Disorder, Archives of General Psychiatry, vol.66, issue.7, pp.713-720, 2009. ,
DOI : 10.1001/archgenpsychiatry.2009.61
Life expectancy among persons with schizophrenia or bipolar affective disorder, Schizophrenia Research, vol.131, issue.1-3, pp.101-104, 2011. ,
DOI : 10.1016/j.schres.2011.06.008
Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998, The British Journal of Psychiatry, vol.182, issue.1, pp.31-36, 2003. ,
DOI : 10.1192/bjp.182.1.31
Amisulpride is an ?atypical? antipsychotic associated with low weight gain, Psychopharmacology, vol.173, issue.1-2, pp.112-115, 2004. ,
DOI : 10.1007/s00213-003-1721-6
Physical illness and schizophrenia: a review of the literature, Acta Psychiatrica Scandinavica, vol.63, issue.9, pp.317-333, 2007. ,
DOI : 10.1016/S0920-9964(02)00314-6
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009. ,
DOI : 10.1016/S0140-6736(08)61764-X
Impact of Hypertension and Body Mass Index on Quality of Life in Schizophrenia, American Journal of Psychiatry, vol.168, issue.5, pp.552-555, 2011. ,
DOI : 10.1176/appi.ajp.2011.10101470
Incidence of Cancer Among Persons With Schizophrenia and Their Relatives, Archives of General Psychiatry, vol.58, issue.6, pp.573-581, 2001. ,
DOI : 10.1001/archpsyc.58.6.573
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1223, 2005. ,
DOI : 10.1056/NEJMoa051688
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics, American Journal of Psychiatry, vol.160, issue.2, pp.290-296, 2003. ,
DOI : 10.1176/appi.ajp.160.2.290
A Randomized Controlled Trial of Olanzapine Versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia, The Journal of Clinical Psychiatry, vol.68, issue.03, pp.368-379, 2007. ,
DOI : 10.4088/JCP.v68n0303
Smoking and schizophrenia, Schizophrenia Research, vol.8, issue.2, pp.93-102, 1992. ,
DOI : 10.1016/0920-9964(92)90024-Y
The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes, Diabetes Care, vol.30, issue.1, pp.8-13, 2007. ,
DOI : 10.2337/dc06-1414
Le syndrome métabolique : comparaison des paramètres biologiques dans différentes définitions. Immuno-ananlyse et biologie spécialisée 19, pp.188-194, 2004. ,
DOI : 10.1016/j.immbio.2004.03.008
Medical Comorbidity in Psychiatric Inpatients: Relation to Clinical Outcomes and Hospital Length of Stay, Psychosomatics, vol.43, issue.1, pp.24-30, 2002. ,
DOI : 10.1176/appi.psy.43.1.24
Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers, Diabetes Care, vol.25, issue.8, pp.1371-1377, 2002. ,
DOI : 10.2337/diacare.25.8.1371
Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study, The British Journal of Psychiatry, vol.183, issue.6, pp.534-539, 2003. ,
DOI : 10.1192/bjp.183.6.534
Clozapine decreases smoking in patients with chronic schizophrenia, Biological Psychiatry, vol.37, issue.8, pp.550-552, 1995. ,
DOI : 10.1016/0006-3223(94)00365-A
Haloperidol increases smoking in patients with schizophrenia, Psychopharmacology, vol.48, issue.1, pp.124-126, 1995. ,
DOI : 10.1007/BF02246063
The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms, Expert Opinion on Drug Safety, vol.275, issue.1, pp.157-168, 2006. ,
DOI : 10.1016/S1474-4422(04)00681-7
Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant, Annals of Internal Medicine, vol.139, issue.10, pp.802-811, 2003. ,
DOI : 10.7326/0003-4819-139-10-200311180-00007
Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions, Annals of Clinical Psychiatry, vol.23, issue.2, pp.131-140, 2011. ,
Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients With Schizophrenia or Related Psychoses, The Journal of Clinical Psychiatry, vol.61, issue.10, pp.742-749, 2000. ,
DOI : 10.4088/JCP.v61n1006
Cardiovascular disease: equity and social determinants Equity, social determinants and public health programmes, 2010. ,
Managing Atypical Antipsychotic???Associated Weight Gain, The Journal of Clinical Psychiatry, vol.65, issue.4, pp.471-477, 2004. ,
DOI : 10.4088/JCP.v65n0404
Novel Antipsychotics and Severe Hyperlipidemia, Journal of Clinical Psychopharmacology, vol.21, issue.4, pp.369-374, 2001. ,
DOI : 10.1097/00004714-200108000-00003
The effects of antipsychotic therapy on serum lipids: a comprehensive review, Schizophrenia Research, vol.70, issue.1, pp.1-17, 2004. ,
DOI : 10.1016/j.schres.2004.01.014
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome, Schizophrenia Research, vol.80, issue.1, pp.9-18, 2005. ,
DOI : 10.1016/j.schres.2005.07.015
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1, Schizophrenia Research, vol.103, issue.1-3, pp.104-109, 2008. ,
DOI : 10.1016/j.schres.2008.04.023
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1, Schizophrenia Research, vol.101, issue.1-3, pp.273-286, 2008. ,
DOI : 10.1016/j.schres.2007.12.487
Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis, The British Journal of Psychiatry, vol.198, issue.6, pp.434-441, 2011. ,
DOI : 10.1192/bjp.bp.109.076950
Plasma Leptin and Antipsychotic-Induced Body Weight Gain, Neuropsychopharmacology, vol.22, issue.9, p.1769, 2005. ,
DOI : 10.1038/sj.npp.1300792
Pronounced Early Increase in Circulating Leptin Predicts a Lower Weight Gain During Clozapine Treatment, Journal of Clinical Psychopharmacology, vol.22, issue.4, pp.424-426, 2002. ,
DOI : 10.1097/00004714-200208000-00015
Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes, Diabetes Care, vol.32, issue.6, pp.1037-1042, 2009. ,
DOI : 10.2337/dc08-1720
Diabetes mellitus in schizophrenic patients, Comprehensive Psychiatry, vol.37, issue.1, pp.68-73, 1996. ,
DOI : 10.1016/S0010-440X(96)90054-1
Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics, European Psychiatry, vol.20, issue.1, pp.65-69, 2005. ,
DOI : 10.1016/j.eurpsy.2004.06.024
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline, Schizophrenia Research, vol.86, issue.1-3, pp.15-22, 2006. ,
DOI : 10.1016/j.schres.2006.06.026
A review of the effect of atypical antipsychotics on weight, Psychoneuroendocrinology, vol.28, pp.83-96, 2003. ,
DOI : 10.1016/S0306-4530(02)00114-2
Dosing the antipsychotic medication olanzapine, Journal of Clinical Psychiatry, vol.58, issue.10, pp.45-49, 1997. ,
Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia, Archives of General Psychiatry, vol.59, issue.4, pp.337-345, 2002. ,
DOI : 10.1001/archpsyc.59.4.337
The Atypical Antipsychotic Therapy and Metabolic Issues National Survey, Journal of Clinical Psychopharmacology, vol.24, pp.1-6, 2004. ,
DOI : 10.1097/01.jcp.0000142281.85207.d5
Second-Generation (Atypical) Antipsychotics and Metabolic Effects, CNS Drugs, vol.161, issue.4, pp.1-93, 2005. ,
DOI : 10.2165/00023210-200519001-00001
Metabolic consideration in the use of antipsychotic medications: a review of recent evidence, Journal of clinical Psychiatry, vol.68, issue.S1, pp.20-27, 2007. ,
Metabolic syndrome and mental illness, American Journal of Managed Care, vol.13, issue.S7, pp.170-177, 2007. ,
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine, Schizophrenia Research, vol.106, issue.2-3, pp.300-307, 2008. ,
DOI : 10.1016/j.schres.2008.09.002
Mortality in a cohort of patients with schizophrenia: a record linkage study, Canadian Journal of Psychiatry, vol.36, issue.4, pp.239-245, 1991. ,
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980???2013: a systematic analysis for the Global Burden of Disease Study 2013, The Lancet, vol.384, issue.9945, pp.766-781, 2014. ,
DOI : 10.1016/S0140-6736(14)60460-8
Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women, JAMA, vol.298, issue.3, pp.299-308, 2007. ,
DOI : 10.1001/jama.298.3.299
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study, European Neuropsychopharmacology, vol.19, issue.8, pp.542-550, 2009. ,
DOI : 10.1016/j.euroneuro.2009.03.003
Enquête épidémiologique de reference sur l'évolution de l'obésité et du surpoids en France ,
Obésité et surpoids. Aide-mémoire n°311, janvier, 2015. ,
The poor physical health of people with mental illness, Western Journal of Medicine, vol.175, issue.5, pp.329-332, 2001. ,
DOI : 10.1136/ewjm.175.5.329
Risk for coronary heart disease in people with severe mental illness: Cross-sectional comparative study in primary care, The British Journal of Psychiatry, vol.188, issue.3, pp.271-277, 2006. ,
DOI : 10.1192/bjp.bp.104.008060
Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database, Archives of General Psychiatry, vol.64, issue.2, pp.242-249, 2007. ,
DOI : 10.1001/archpsyc.64.2.242
Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study, BMJ, vol.321, issue.7259, pp.483-484, 2000. ,
DOI : 10.1136/bmj.321.7259.483
Mortality and causes of death in schizophrenia in Stockholm County, Sweden, Schizophrenia Research, vol.45, issue.1-2, pp.21-28, 2000. ,
DOI : 10.1016/S0920-9964(99)00191-7
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study, The British Journal of Psychiatry, vol.187, issue.2, pp.137-179, 2005. ,
DOI : 10.1192/bjp.187.2.137
Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis, BMC Psychiatry, vol.18, issue.6, 2014. ,
DOI : 10.3109/09638230903111114
The Lipid Treatment Assessment Project (L-TAP), Archives of Internal Medicine, vol.160, issue.4, pp.459-467, 2000. ,
DOI : 10.1001/archinte.160.4.459
NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X, Diabetologia, vol.23, issue.2, pp.1286-92, 1997. ,
DOI : 10.1007/s001250050822
Effects of TNF-?? on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations, Journal of Laboratory and Clinical Medicine, vol.139, issue.3, pp.140-146, 2002. ,
DOI : 10.1067/mlc.2002.121552
Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol, Journal of Psychiatry & Neuroscience, vol.26, pp.137-149, 2001. ,
Suicidal Behavior in Patients With Schizophrenia and Other Psychotic Disorders, American Journal of Psychiatry, vol.156, issue.10, pp.1590-1595, 1999. ,
DOI : 10.1176/ajp.156.10.1590
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death, New England Journal of Medicine, vol.360, issue.3, pp.225-260, 2009. ,
DOI : 10.1056/NEJMoa0806994
Role of Insulin Resistance in Human Disease, Diabetes, vol.37, issue.12, pp.1595-1607, 1988. ,
DOI : 10.2337/diab.37.12.1595
The Metabolic Syndrome: Requiescat in Pace, Clinical Chemistry, vol.51, issue.6, pp.931-938, 2005. ,
DOI : 10.1373/clinchem.2005.048611
The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases, New England Journal of Medicine, vol.338, issue.21, pp.1516-1520, 1998. ,
DOI : 10.1056/NEJM199805213382106
Metabolic side effects of antipsychotic drug treatment ??? pharmacological mechanisms, Pharmacology & Therapeutics, vol.125, issue.1, pp.169-179, 2010. ,
DOI : 10.1016/j.pharmthera.2009.10.010
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder, Schizophrenia Research, vol.57, issue.2-3, pp.209-219, 2002. ,
DOI : 10.1016/S0920-9964(01)00312-7
Prise de poids pharmaco-induite par les psychotropes et sa prise en charge : revue des donn??es de la litt??rature, L'Enc??phale, vol.31, issue.4, pp.507-516, 2005. ,
DOI : 10.1016/S0013-7006(05)82412-1
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis, Schizophrenia Research, vol.123, issue.2-3, pp.225-233, 2010. ,
DOI : 10.1016/j.schres.2010.07.012
Physical consequences of schizophrenia and its treatment, Life Sciences, vol.71, issue.3, pp.239-257, 2002. ,
DOI : 10.1016/S0024-3205(02)01646-6
The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia, Life Sciences, vol.74, 1999. ,
Evidence of basal pituitary???adrenal overactivity in first episode, drug na??ve patients with schizophrenia, Psychoneuroendocrinology, vol.29, issue.8, pp.1065-1070, 2004. ,
DOI : 10.1016/j.psyneuen.2003.08.011
Weight gain associated with use of psychotropic medications, Journal of Clinical Psychiatry, vol.60, pp.16-19, 1999. ,
A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Archive General of, Psychiatry, vol.64, pp.1123-1154, 2007. ,
Drug-induced diabetes mellitus: the example of atypical antipsychotics, Revue Medicale de Liege, vol.60, pp.5-6, 2005. ,
Abnormal glucose metabolism in??patients treated with antipsychotics, Diabetes & Metabolism, vol.33, issue.3, pp.169-175, 2007. ,
DOI : 10.1016/j.diabet.2007.01.003
Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up, European Psychiatry, vol.27, issue.1, pp.33-42, 2012. ,
DOI : 10.1016/j.eurpsy.2011.02.009
Central nervous system control of food intake, Nature, vol.404, issue.6778, pp.661-671, 2000. ,
Insulin resistance and atherosclerosis, Journal of Clinical Investigation, vol.116, issue.7, pp.1813-1835, 2006. ,
DOI : 10.1172/JCI29024DS1
Effets des troubles métaboliques sur la qualité de vie des personnes atteintes de problème de santé mentale, Partenaire, vol.19, issue.4, pp.9-12, 2011. ,
Vascular function, insulin resistance and fatty acids, Diabetologia, vol.45, issue.5, pp.623-657, 2002. ,
DOI : 10.1007/s00125-002-0800-2
Nutritional Assessment of Patients With Schizophrenia: A Preliminary Study, Schizophrenia Bulletin, vol.29, issue.2, pp.393-397, 2003. ,
DOI : 10.1093/oxfordjournals.schbul.a007013
Atypical antipsychotics and weightgain - a systematic review, Acta Psychiatrica Scandinavica, vol.101, issue.6, pp.416-432, 2000. ,
DOI : 10.1034/j.1600-0447.2000.101006416.x
Eating disorder and epilepsy in mice lacking 5-HT2C
serotonin receptors, Nature, vol.374, issue.6522, pp.542-546, 1995. ,
DOI : 10.1038/374542a0
Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia, International Journal of Obesity, vol.26, issue.1, pp.137-141, 2002. ,
DOI : 10.1038/sj.ijo.0801840
Metabolic disturbance in first-episode schizophrenia, The British Journal of Psychiatry, vol.184, issue.47, pp.76-79, 2004. ,
DOI : 10.1192/bjp.184.47.s76
Physical health of patients with schizophrenia, Psychiatry, vol.4, issue.11, pp.58-60, 2005. ,
DOI : 10.1383/psyt.2005.4.11.58
Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication, Journal of Psychiatric Research, vol.35, issue.6, pp.339-345, 2001. ,
DOI : 10.1016/S0022-3956(01)00041-3
Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12,103 individuals with and without contact with psychiatric services, Clinical Practice and Epidemiology in Mental Health, vol.4, pp.4-23, 2008. ,
Syndrome métabolique : diagnostic, conséquences cardiaques et vasculaires, EMC-Cardiologie Angéiologie, pp.423-430, 2005. ,
Peripheral Factors in the Metabolic Syndrome: The Pivotal Role of Adiponectin, Annals of the New York Academy of Sciences, vol.50, issue.1, pp.185-95, 2006. ,
DOI : 10.1210/jc.2003-031826
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia, Psychiatry Research, vol.177, issue.3, pp.271-279, 2010. ,
DOI : 10.1016/j.psychres.2010.03.011
Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia, Psychiatry Research, vol.207, issue.1-2, pp.25-32, 2013. ,
DOI : 10.1016/j.psychres.2012.09.026
Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity, European Neuropsychopharmacology, vol.16, pp.142-148, 2006. ,
DOI : 10.1016/j.euroneuro.2006.06.005
Mechanisms linking obesity with cardiovascular disease, Nature, vol.105, issue.7121, pp.875-80, 2006. ,
DOI : 10.1038/nature05487
The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease, American Journal of Clinical Nutrition International Journal of Psychiatry in Medicine, vol.4, issue.25, pp.20-34, 1956. ,
Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study, The British Journal of Psychiatry, vol.173, issue.4, pp.325-334, 1998. ,
DOI : 10.1192/bjp.173.4.325
Insulin Sensitivity, Insulin Secretion, and Abdominal Fat: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study, Diabetes, vol.52, issue.10, pp.2490-2496, 2003. ,
DOI : 10.2337/diabetes.52.10.2490
Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia, Annual Review of Clinical Psychology, vol.4, issue.1, pp.189-216, 2008. ,
DOI : 10.1146/annurev.clinpsy.4.022007.141248
Cigarette Smoking in Patients with Schizophrenia in China: Prospective, Multicentre Study, Australian & New Zealand Journal of Psychiatry, vol.18, issue.5, pp.456-62, 2010. ,
DOI : 10.1016/j.ahj.2005.02.007
Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study, Schizophrenia Research, vol.138, issue.1, pp.54-57, 2012. ,
DOI : 10.1016/j.schres.2012.02.021
Clozapine Use and Risk of Diabetes Mellitus, Journal of Clinical Psychopharmacology, vol.22, issue.3, pp.236-279, 2002. ,
DOI : 10.1097/00004714-200206000-00002
Smoking as a Modifiable Risk Factor for Type 2 Diabetes in Middle-Aged Men, Diabetes Care, vol.24, issue.9, pp.1590-1595, 2001. ,
DOI : 10.2337/diacare.24.9.1590
Metabolic Syndrome vs Framingham Risk Score for Prediction of Coronary Heart Disease, Stroke, and Type 2 Diabetes Mellitus, Archives of Internal Medicine, vol.165, issue.22, pp.2644-2650, 2005. ,
DOI : 10.1001/archinte.165.22.2644
Atypical antipsychotic drugs and long-term outcome in schizophrenia, Journal of Clinical Psychiatry, vol.57, pp.53-60, 1996. ,
Obesity as a risk factor for antipsychotic noncompliance, Schizophrenia Research, vol.66, issue.1, pp.51-57, 2004. ,
DOI : 10.1016/S0920-9964(02)00498-X
Influence of antipsychotics on mortality in schizophrenia: Systematic review, Schizophrenia Research, vol.113, issue.1, pp.1-11, 2009. ,
DOI : 10.1016/j.schres.2009.05.018
The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity, The American Journal of Medicine, vol.105, issue.2, pp.145-150, 1998. ,
DOI : 10.1016/S0002-9343(98)00190-9
Bodyweight Gain with Atypical Antipsychotics, Drug Safety, vol.62, issue.1, pp.59-73, 2001. ,
DOI : 10.2165/00002018-200124010-00005
Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect, Schizophrenia Research, vol.79, issue.2-3, pp.323-335, 2005. ,
DOI : 10.1016/j.schres.2005.04.016
The Effects of Novel Antipsychotics on Glucose and Lipid Levels, The Journal of Clinical Psychiatry, vol.63, issue.10, pp.856-865, 2002. ,
DOI : 10.4088/JCP.v63n1002
The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics -a retrospective medical records review.Psychiatria Danubia, pp.314-336, 2012. ,
Cardiovascular procedures in patients with mental disorders, JAMA, vol.283, pp.3198-3199, 2000. ,
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol, The British Journal of Psychiatry, vol.187, issue.6, pp.537-543, 2005. ,
DOI : 10.1192/bjp.187.6.537
Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia, The British Journal of Psychiatry, vol.184, issue.1, pp.58-62, 2004. ,
DOI : 10.1192/bjp.184.1.58
Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients, Schizophrenia Research, vol.71, issue.1, pp.137-144, 2004. ,
DOI : 10.1016/j.schres.2003.11.005
Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients, Journal of Psychiatric Research, vol.37, issue.3, pp.193-220, 2003. ,
DOI : 10.1016/S0022-3956(03)00018-9